About Us

At Exposomics, we believe health is shaped by more than genetics. It’s also shaped by the environments we live in every day. Air pollution, UV radiation, and noise all leave their mark over a lifetime, and together they make up what scientists call the exposome. We build technology that measures these exposures and turns them into clear, personalized insights, so people can make informed choices about their health. Our mission is to give everyone the knowledge to take control of their environmental health and to help create a healthier world for all.

Exposomics is making envrionemental exposures measurable and usable

Our Team

Michael Snyder, PhD

Co-Founder

Dr. Snyder is the Stanford Ascherman Professor and the Director of the Center of Genomics and Personalized Medicine. He is a leader in the field of functional genomics and proteomics. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and currently carries out a variety of projects in the areas of genomics and proteomics both in yeast and humans. These include the large-scale analysis of proteins using protein microarrays and the global mapping of the binding sites of chromosomal proteins. His laboratory built the first proteome chip for any organism and the first high resolution tiling array for the entire human genome.

Xinyue ‘Allison’ Zhang, PhD

Co-Founder | Chief Executive Officer

Dr. Zhang is an expert in exposome research. Her research focuses on understanding the human exposome, particularly, how the exposome affects human health. She is interested in applying multi-omics approaches using high-throughput sequencing, mass-spectrometry, and wearable devices to understand the exposome and its health consequences at the personal level. She has developed a wearable device to capture the personal exposome and has studied the human exposome in multiple environmental settings.

Fanqing Frank Chen, PhD

Chief Technology Officer

Dr. Fanqing Frank Chen has been founder for several successful companies, including Optokey, Inc., a nanophotonics company focusing on miniaturized high data content measurement technology for chemical analysis and healthcare. He is an expert in the field of life sciences, chemistry, material sciences, and nanotechnology. He specializes in helping clients in these industries through R&D collaborations, or helping to identify partner companies for M&A and corporate equity investments.

Jeremy Woods, MD

Chief Medical Officer

Dr. Woods is an expert on genomic medicine with a special focus innovative data solutions to clinical and public health problems. As a clinical geneticist he has participated in innovative projects such as the trial leading to FDA approval for the first gene therapy for Duchenne muscular dystrophy, the Undiagnosed Diseases Network, and Project Baby Bear genotyping. He is a pioneer in point of care genotyping with a specific interest in pharmacogenetics and automated environmental pathogen detection.